China cannot position itself as a Mecca for clinical trials due to its ongoing lack of transparency, an inability to protect patients and inadequate infrastructure, writes Anne Poli, a senior consultant at Boston's Halloran Consulting Group. She said the country has - on the face of it - made an effort to align its industry with the Good Clinical Practice guidelines and pledged to implement International Conference on Harmonization recommendations. But she added: "The reality is that there are still many unanswered questions about how this will work in practice.
China cannot position itself as a Mecca for clinical trials due to its ongoing lack of transparency, an inability to protect patients and inadequate infrastructure, writes Anne Poli, a senior consultant at Boston's Halloran Consulting Group. She said the country has - on the face of it - made an effort to align its industry with the Good Clinical Practice guidelines and pledged to implement International Conference on Harmonization recommendations. However, Poli warned that in reality, few concrete steps have been taken, with ongoing issues including clinical trial investigators tasked with interpreting the guidelines.